Journal Article

Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial

Wacholder, Sholom, Herrero, Rolando, Quint, Wim, Hildesheim, Allan, van Doorn, Leen-Jan, Hu, Shangying, Kemp, Troy J, Lowy, Douglas R, Cortes, Bernal, Jiménez, Silvia E, Rodríguez, Ana Cecilia, González, Paula, Pinto, Ligia A, Schiller, John T, Rodriguez, Ana Cecilia, Kreimer, Aimée R., Struijk, Linda, Tsang, Sabrina H., Porras, Carolina, Wagner, Sarah, Palefsky, Joel M, Kreimer, Aimée R, Romero, Byron, Carvajal, Loretto, Schiffman, Mark, Sherman, Mark, Darragh, Teresa M, Sidawy, Mary K, Sampson, Joshua N., Sierra, Mónica S., Cortés, Bernal, Stoler, Mark H, Schussler, John

2023

Overview

IntroductionHuman papillomavirus (HPV) vaccines protect against incident HPV infections, which cause cervical cancer.ObjectivesWe estimated the prevalence and incidence of HPV infections in young adult women to understand the impact of an HPV vaccination programme in this population.MethodsWe collected cervical specimens from 6322 unvaccinated women, aged 18–37 years, who participated in the Costa Rica Vaccine Trial and its long-term follow-up. Women were followed for (median) 4.8 years and had (median) 4.0 study visits. Cervical specimens were tested for the presence/absence of 25 HPV genotypes. For each age band, we estimated the percentage of women with 1+ prevalent or 1+ incident HPV infections using generalised estimating equations. We also estimated the prevalence and incidence of HPV as a function of time since first sexual intercourse (FSI).ResultsThe model estimated HPV incident infections peaked at 28.0% (95% CI 25.3% to 30.9%) at age 20 years then steadily declined to 11.8% (95% CI 7.6% to 17.8%) at age 37 years. Incident oncogenic HPV infections (HPV16/18/31/33/35/39/45/51/52/56/58/59) peaked and then declined from 20.3% (95% CI 17.9% to 22.9%) to 7.7% (95% CI 4.4% to 13.1%); HPV16/18 declined from 6.4% (95% CI 5.1% to 8.1%) to 1.1% (95% CI 0.33% to 3.6%) and HPV31/33/45/52/58 declined from 11.0% (95% CI 9.3% to 13.1%) to 4.5% (95% CI 2.2% to 8.9%) over the same ages. The percentage of women with 1+ incident HPV of any, oncogenic, non-oncogenic and vaccine-preventable (HPV16/18, HPV31/33/45, HPV31/33/45/52/58, and HPV6/11) types peaked <1 year after FSI and steadily declined with increasing time since FSI (p for trends <0.001). We observed similar patterns for model estimated HPV prevalences.ConclusionYoung adult women may benefit from HPV vaccination if newly acquired vaccine-preventable oncogenic infections lead to cervical precancer and cancer. HPV vaccination targeting this population may provide additional opportunities for primary prevention.Trial registration number NCT00128661.

• Publisher: BMJ Publishing Group Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Cervical cancer / Condoms / epidemiology / Human papillomavirus / Immunization / Infections / Latin America / Original Research / papillomaviridae / Sexually transmitted diseases / STD / vaccination / Vaccines / Women / Young adults